In a patient with treatment-refractory idiopathic inflammatory myositis, reinfusion of CD19 CAR T cells following disease relapse led to the development of T cells targeting the CD19 CAR and no clinical improvement, with drug-free remission induced again after treatment with BCMA CAR T cells. Here, CD19 is linked to acquired idiopathic inflammatory myopathy.